Clear Choice Laser is now offering procedures using the KXL® System, the first and only FDA-approved therapy for progressive keratoconus. The machine, created by Avedro, was approved in April, along with Avedro’s Photrexa® Viscous and Photrexa® solutions, and is being used in about 100 facilities nationwide.
This system is used to treat keratoconus, a condition in which the cornea (the front clear window of the eye) becomes weak, thin, or irregularly shaped. Corneas with keratoconus can bulge forward into a cone shape, causing poor vision. It affects 1 in 750 Americans, and while the preliminary stages simply necessitate glasses, eventually the condition may require a corneal transplant.
The KXL® System facilitates corneal collagen cross-linking, a keratoconus treatment that has been in use since 1998. It combines the use of ultraviolet light and riboflavin to strengthen collagen fibrils on the cornea. This makes the cornea more rigid, and less likely to worsen over time.
Would you like to be contacted about corneal cross-linking?
Would you like to download a brochure to learn more about corneal cross-Linking?
Frequently Asked Questions
Cost of being in the study: You will be charged for the procedure and will still have to pay for the costs of your regular medical care. Since this procedure is investigational, insurance plans typically do not cover the costs for participating. Financing is available to help our patients pay for this investigational procedure. To find out more about costs, ask the study doctor or staff. For more information about keratoconus, and/or our diagnostic screenings and treatments, please call our practice and ask to speak with a CXL coordinator.
- Wollensak G, Spoerl E, Seiler T.; Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. AJO 2003 May;135(5):620-7
- Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE.; Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg. 2008 May;34(5):796-801.
- Coskunseven E, Jankov MR 2nd, Hafezi F.; Contralateral eye study of corneal collagen cross-linking with riboflavin and UVA irradiation in patients with keratoconus.
J Refract Surg. 2009 Apr;25(4):371-376
- Grewal DS, Brar GS, Jain R, Sood V, Singla M, Grewal SP.; Corneal collagen crosslinking using riboflavin and ultraviolet-A light for keratoconus: one-year analysis using Scheimpflug imaging. J Cataract Refract Surg. 2009 Mar;35(3):425-32.
- Spoerl E, Mrochen M, Sliney D, Trokel S, Seiler T.; Safety of UVA-riboflavin cross-linking of the cornea. Cornea. 2007 May;26(4):385-9.
- Trattler W, Rubinfeld R, Corneal Collagen Cross-linking; Cataract and Refractive Surgery Today; September 2009
- Caporossi A, Mazzotta C, Baiocchi S, Caporossi T. Long-term Results of Riboflavin Ultraviolet A Corneal Collagen Cross-linking for Keratoconus in Italy: The Siena Eye Study. Am Journal of Ophthalmology 2010:149:585-593 www.ajo.com/article/S0002-9394(09)00808-3/abstract
- Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cat Ref Surg. 2008
- Vinciguerra P, Albè E, Trazza S, Seiler T, Epstein D. Intraoperative and postoperative effects of corneal collagen cross-linking on progressive keratoconus. Arch Ophth. 2009
- Daley, R. Cornea
Cross-linking vision improvement evidence mounts. Eyeworld, 2010. http://www.eyeworld.org/article.php?sid=5268&strict=&morphologic=&query=Daley, R. Corneal%26%238232%3BCross-linking vision improvement evidence mounts.
- Rubinfeld RS, Trattler WB, Martin NF, Adi MA and The CXL-USA Study Group: Answering Your Patients’ Questions About Cross-Linking; Advanced Ocular Care. March 2010:25-28
- Boxer Wachler BS, Pinelli R, Ertan A, Colin CKC. Safety and efficacy of transepithelial crosslinking (C3-R/CXL), J CATARACT REFRACT SURG – VOL 36, Pgs 186-187, JANUARY 2009
- Pinelli R, El Beltagi T, Leccisotti A. Update on Corneal Crosslinking. Cataract and Refractive Surgery Today October 2008: 67-69. http://www.crstodayeurope.com/Issues/1008/1008_19.php